Our broad range of GMP products covers pharmaceutical raw materials for the development and manufacturing of solid, semi-solid and liquid dosage forms for small and large molecules. Additionally, we offer a portfolio of drug delivery compounds (DDCs), as well as solutions for solubility enhancement and controlled release.

Speed up your raw material qualification process and benefit from our application know-how and regulatory support consisting of the comprehensive Emprove® Dossier Library.

View of functionalized polyethylene glycol (PEG) used to enhance stability of PEGylated therapeutic protein
Activated & Functionalized PEGs

Our portfolio of customizable GMP biodegradable polymers, synthetic lipids, and functionalized polyethylene glycols enables you to create drug formulations for small molecules, peptides, proteins, and nucleic acids with optimized kinetics to maximize drug product efficacy.

Biomolecule Formulation
Biomolecule Formulation

Specifically developed for high-risk biopharmaceutical applications, we offer a wide range of buffers, salts and stabilizers low in bioburden and endotoxins. Supported by extensive documentation, they help you to minimize regulatory and quality-associated risks of your biomolecule formulation.

Granulated raw materials for drug applications
Granulated Materials

Free-flowing and easy to handle, our granulated raw materials reduce caking and clumping for enhanced processability, increased manufacturing process speed and improved operator safety in your pharmaceutical manufacturing process.

Injectables & Parenteral Formulations
Injectables & Parenteral Formulations

Find high-quality, pure, and reliable raw material solutions to meet your parenteral formulation requirements.

Injectable liquid formulation
Liquid Formulation

As your ideal partner for liquid dosage formulation, we provide excipients for both small molecule and large molecule formulations, as well as for liquid formulations targeting different administration routes such as ophthalmics, nasal, parenteral, oral, and otic preparations.

Tableting formulation
Parteck® Functional Excipients

Particle-engineered Parteck® excipients give your solid dose formulations the functionalities you need for tableting processes, specific drug delivery technologies, or solubility enhancement, backed by stringent quality control and regulatory support.

Polymeric Delivery Platforms
Polymeric Delivery Platforms

We provide manufacturing, process development, and formulation services to help overcome formulation challenges when developing injectable sustained release drug products for large peptides and proteins.

Parenteral formulations using protein stabilizers
Protein Stabilizers

Developed for small- or large-volume parenteral applications, our portfolio of high-quality sugars, polyols, and amino acids simplifies selection when you face critical challenges such as preventing aggregation during biopharmaceutical manufacturing.

Semi-solid formulations.
Semisolid Formulation

Draw on our high-quality pharma raw materials supporting rapid formulation of semi-solid dosage forms, e.g. for topical administration and transdermal drug delivery, backed by global regulatory know-how that enables you to bring your product to market faster.

Newly produced tablets held in the gloved hands of a pharmaceutical worker
Solid Formulation

Our comprehensive portfolio of high-quality raw materials and functionalized excipients helps you meet the challenges of solid formulation pharmaceutical manufacturing, backed by regulatory support for simplified supplier qualification, accelerated processes, and reduced total cost of ownership.

Cross-section view of liposome used in drug product development and manufacturing
Synthetic Lipids

As a highly specialized manufacturer, we focus on the tailored manufacturing of synthetic lipids for our customers. Our portfolio lipids include synthetic lipids with higher stability, solubility, and improved handling characteristics. All our lipids are being used in various clinical trials, and some also in marketed drug products.

Reducing viscosity of highly concentrated monoclonal antibody (mAb) formulation to enable subcutaneous delivery
Viscosity Reduction Platform

Our viscosity reduction platform enables increased target concentrations of your protein therapeutics, simplifying biotherapeutic manufacturing, improving dosing requirement and making self-medication via the subcutaneous route possible.